Evaxion Biotech A/S
EVAX2.720USD
+0.110+4.21%
Market hours （ET）Quotes delayed by 15 min
38.15MMarket Cap
LossP/E TTM
More Details of Evaxion Biotech A/S Company
Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Company Info
Ticker SymbolEVAX
Company nameEvaxion A/S
IPO dateFeb 05, 2021
CEO- -
Number of employees46
Security typeDepository Receipt
Fiscal year-endFeb 05
AddressDr. Neergaards Vej 5F
CityHOERSHOLM
Stock exchangeNASDAQ Capital Market Consolidated
CountryDenmark
Postal code2970
Phone
Websitehttps://evaxion.ai/
Ticker SymbolEVAX
IPO dateFeb 05, 2021
CEO- -
Company Executives
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jun 4
Updated: Wed, Jun 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Merck & Co Inc
19.22%
Merck Sharp & Dohme Corporation
3.84%
Ikarian Capital LLC
1.27%
Boothbay Fund Management, LLC
0.38%
XTX Markets LLC
0.26%
Other
75.03%
Shareholders
Shareholders
Proportion
Merck & Co Inc
19.22%
Merck Sharp & Dohme Corporation
3.84%
Ikarian Capital LLC
1.27%
Boothbay Fund Management, LLC
0.38%
XTX Markets LLC
0.26%
Other
75.03%
Shareholder Types
Shareholders
Proportion
Corporation
23.07%
Hedge Fund
1.27%
Investment Advisor/Hedge Fund
0.44%
Venture Capital
0.26%
Investment Advisor
0.15%
Research Firm
0.04%
Other
74.78%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
32
1.59M
25.22%
+1.30M
2025Q1
32
1.59M
25.25%
+1.31M
2024Q4
38
446.77K
85.54%
+141.60K
2024Q3
37
392.71K
134.00%
+108.52K
2024Q2
37
264.60K
41.03%
-4.56K
2024Q1
38
250.14K
40.21%
+46.25K
2023Q4
37
182.88K
44.77%
-12.75K
2023Q3
38
176.61K
33.39%
-25.06K
2023Q2
38
177.16K
33.49%
-28.21K
2023Q1
40
179.10K
33.89%
-23.83K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Merck & Co Inc
1.21M
19.22%
+1.11M
+1019.46%
Mar 31, 2025
Merck Sharp & Dohme Corporation
242.82K
3.84%
+134.37K
+123.89%
Jan 31, 2025
Ikarian Capital LLC
80.00K
1.27%
+80.00K
--
Mar 31, 2025
Boothbay Fund Management, LLC
23.73K
0.38%
+23.73K
--
Mar 31, 2025
XTX Markets LLC
16.28K
0.26%
+16.28K
--
Mar 31, 2025
UBS Financial Services, Inc.
6.52K
0.1%
+6.52K
--
Mar 31, 2025
GAMMA Investing LLC
4.87K
0.08%
+4.87K
--
Mar 31, 2025
SBI Securities Co., Ltd.
2.46K
0.04%
+2.40K
+3690.77%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
2.21K
0.04%
+2.15K
+3710.34%
Mar 31, 2025
Beacon Capital Management, LLC
972.00
0.02%
-1.00
-0.10%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 27, 2024
Merger
5<1
Dec 27, 2024
Merger
5<1
Dec 27, 2024
Merger
5<1
Dec 27, 2024
Merger
5<1
Jan 08, 2024
Merger
10<1
Jan 08, 2024
Merger
10<1
Date
Type
Ratio
Dec 27, 2024
Merger
5<1
Dec 27, 2024
Merger
5<1
Dec 27, 2024
Merger
5<1
Dec 27, 2024
Merger
5<1
Jan 08, 2024
Merger
10<1
Jan 08, 2024
Merger
10<1
Jan 08, 2024
Merger
10<1
Jan 08, 2024
Merger
10<1
